How should acitrom (acenocoumarol) be managed perioperatively in a patient with a mechanical mitral valve replacement?

Perioperative Management of Acitrom (Acenocoumarol) in Mechanical Mitral Valve Patients

For patients with a mechanical mitral valve replacement on acitrom (acenocoumarol) undergoing noncardiac surgery, bridging anticoagulation with therapeutic-dose heparin is recommended during the perioperative period when the INR falls below therapeutic range, given the high thrombotic risk of mitral mechanical valves. 1

Understanding Acitrom

Acitrom is the brand name for acenocoumarol, a vitamin K antagonist (VKA) similar to warfarin but with a shorter half-life. 2, 3 It functions identically to other VKAs in terms of anticoagulation management principles. 4

Chronic Anticoagulation Target for Mechanical Mitral Valves

• Target INR of 3.0 (range 2.5-3.5) is mandatory for all mechanical mitral valve replacements, regardless of valve generation or additional risk factors. 1
• This higher target compared to aortic mechanical valves (INR 2.5) reflects the significantly greater thrombotic risk in the mitral position. 1
• Addition of low-dose aspirin 75-100 mg daily may be considered when bleeding risk is low, though this increases hemorrhagic complications. 1

Perioperative Management Algorithm

For Minor Procedures (Low Bleeding Risk)

Continue acenocoumarol with therapeutic INR for procedures where bleeding is easily controlled, such as dental extractions or cataract surgery. 1

For Major Surgery (Moderate to High Bleeding Risk)

High-risk patients with mechanical mitral valves require bridging anticoagulation:

1. Stop acenocoumarol 5-6 days before surgery (may be shorter than warfarin given acenocoumarol's shorter half-life). 1

2. Initiate therapeutic-dose bridging when INR falls below 2.0 (typically 48 hours preoperatively):

   • Intravenous unfractionated heparin (UFH): Stop 4-6 hours before procedure 1
   • Low-molecular-weight heparin (LMWH): 100 U/kg every 12 hours, with last dose 24 hours before surgery 1

3. Restart acenocoumarol within 12-24 hours postoperatively once hemostasis is achieved. 1

4. Resume therapeutic-dose heparin as early as bleeding stability allows and continue until INR is therapeutic (≥2.0). 1

Critical Distinction from Low-Risk Patients

Unlike patients with bileaflet mechanical aortic valves and no risk factors (who may not require bridging), mechanical mitral valve patients are categorically high-risk and warrant bridging therapy. 1 The PERIOP-2 trial demonstrated no thrombotic events in mechanical valve patients with appropriate perioperative management, though bridging increases bleeding risk. 1

Management of Supratherapeutic INR

For elevated INR (>1.5) 1-2 days before surgery:

• Routine vitamin K is NOT recommended as it may create warfarin resistance postoperatively. 1
• Consider small doses (1 mg oral) only if INR remains >1.5 on day of surgery. 1

For emergency surgery with therapeutic INR:

• Administer 4-factor prothrombin complex concentrate for rapid reversal (onset 5-15 minutes). 1
• Fresh frozen plasma is an alternative but has slower onset (1-4 hours) and shorter duration. 1

Monitoring and Compliance

• Target time in therapeutic range should exceed 70% for optimal outcomes. 5
• Acenocoumarol requires the same INR monitoring frequency as warfarin. 2, 3
• Common causes of INR derangement include infectious processes, poor compliance, dietary changes, and drug interactions. 5
• Patient education regarding consistent dosing, dietary vitamin K intake, and medication interactions is essential. 1, 5

Management of Thromboembolic Events on Therapeutic Anticoagulation

If stroke or systemic embolism occurs despite therapeutic INR (2.5-3.5):

• Increase INR target to 4.0 (range 3.5-4.0), OR 1
• Add aspirin 75-100 mg daily after careful bleeding risk assessment 1
• Exclude endocarditis, assess for new atrial fibrillation, and evaluate for hypercoagulable states. 1

Key Pitfalls to Avoid

• Never use direct oral anticoagulants (DOACs) in mechanical valve patients - dabigatran is contraindicated and other DOACs are not recommended. 1
• Do not withhold bridging in mechanical mitral valve patients based on aortic valve data - mitral position carries substantially higher thrombotic risk. 1
• Avoid high-dose vitamin K for routine perioperative management as it complicates postoperative re-anticoagulation. 1
• Do not target lower INR ranges (<2.5) in mitral mechanical valves even in the absence of additional risk factors. 1